The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet
Abstract
AIMS: The major aims of the study were to compare the safety of a continuous low-dose estradiol-releasing vaginal ring (ESTring) to that of a vaginal estradiol tablet (Vagifem) on the endometrium and the relief of subjective symptoms and signs of urogenital estrogen deficiency. Quality of life and acceptability of treatment delivery were also assessed. STUDY DESIGN: A prospective, randomized study in which women were assigned in a 2:1 ratio to ESTring and Vagifem and followed for 12 months. The primary endpoint was endometrial safety, based on the results of ultrasound measurement of endometrial thickness and a progestogen challenge test at baseline and week 48. Efficacy was determined by subjective assessment of urogenital estrogen deficiency symptoms at baseline and weeks 3, 12, 24, 36 and 48 and assessment of signs of vaginal epithelial atrophy by the clinician at baseline, 12 and 48 weeks. In addition, pelvic floor strength, vaginal cytological evaluation and pH, bacteruria and patient acceptability were assessed. Quality of life was assessed using a menopause-specific quality-of-life questionnaire and a 2-day bladder diary at baseline and 12 and 48 weeks. The comparability of the two groups was assessed using ANOVA, chi2 or Fisher's exact tests. RESULTS: A total of 126 women were randomized to ESTring and 59 to Vagifem. There was no statistical difference between the groups in the alleviation of symptoms and signs of urogenital estrogen deficiency. Maturation indices increased in both groups, from generally atrophic at baseline to proliferative or highly proliferative at 48 weeks. After 48 weeks of treatment, there was no statistically significant difference in endometrial thickness between the two groups. A statistically smaller proportion of bleeding/spotting occurred in the ESTring group (n = 0) compared to the Vagifem users (n = 4). Estradiol and total estrone serum levels increased during treatment in both groups but remained within the normal postmenopausal range. General health status in both groups was unchanged but the urogenital component of health burden was significantly improved in both groups. Bladder diary variables showed no differences between treatment groups. CONCLUSION: Equivalent endometrial safety and efficacy in the relief of the symptoms and signs of urogenital estrogen deficiency were demonstrated for the 12 months' use of a low-dose estradiol-releasing vaginal ring and a vaginal estradiol tablet.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hormone treatment of endometriosis: The estrogenthreshold hypothesis
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91706-g · Cited by 335
Cited by
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Local oestrogen for vaginal atrophy in postmenopausal women
Lethaby, A., Ayeleke, R. O., & Roberts, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001500.pub3 · Cited by 601
(2013) · Menopause · doi:10.1097/gme.0b013e3182a122c2 · Cited by 560
(2020) · Menopause · doi:10.1097/gme.0000000000001609 · Cited by 531
Recommendations for the management of postmenopausal vaginal atrophy
Sturdee, D. W., & Panay, N. (2010) · Climacteric · doi:10.3109/13697137.2010.522875 · Cited by 527
Metadata
- Authors
- Weisberg, E., Ayton, R., Darling, G., Farrell, E., Murkies, A., O'Neill, S., Kirkegard, Y., & Fraser, I.
- Venue
- Climacteric
- Publisher
- Informa UK Limited
- Published
- 2005-03
- Volume
- 8
- Issue
- 1
- Pages
- 83-93
- ISSN
- 1369-7137 (ISSN-L)
- 1473-0804
- OpenAlex
- W1994597465
- Cited by
- 159
- References
- 1
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. https://app.cochat.ai/papers/10.1080/13697130500087016
- The paper
- Weisberg, E., Ayton, R., Darling, G., Farrell, E., Murkies, A., O'Neill, S., Kirkegard, Y., & Fraser, I. (2005). Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. https://doi.org/10.1080/13697130500087016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.